Beam Therapeutics Inc.
- BEAM
- NASDAQ
- Biotechnology
- Gene Editing (Base Editing)
- Biotech (Genetic Medicine)
$24.19
Today +3.07%Quote Oct 19, 2026, 08:00 PM UTC
−4.86%over the last month
Max drawdown −9.5%From 1-month high −9.5%3 months −10.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Beam Therapeutics
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States.
Where the money comes from
Q2 2011 revenue $1.59B
- Home And Security$889.7M55.9%
- Spirits$702.7M44.1%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
540
Founded
2017
Market value
$2.50B
Quote Oct 19
Floor
$23.92
1.1% below price
Resistance
$24.44
1.0% above price
Price vs analyst targets
27 analysts
Lowest target
$39.00Highest target
$80.00
$39.00Highest target
$80.00
- Price $24.19
- Average target $59.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 146% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about BEAMPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free